UBS Group’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-342,200
| Closed | -$29.1M | – | 8869 |
|
|
2019
Q4 | $29.1M | Sell |
342,200
-50,200
| -13% | -$3.35M | 0.01% | 1118 |
|
|
2019
Q3 | $19.6M | Buy |
392,400
+107,400
| +38% | +$4.28M | 0.01% | 1257 |
|
|
2019
Q2 | $10.4M | Buy |
+285,000
| New | +$9.3M | ﹤0.01% | 1723 |
|
|
2017
Q3 | – | Sell |
-9,800
| Closed | -$373K | – | 8166 |
|
|
2017
Q2 | $373K | Hold |
9,800
| – | – | ﹤0.01% | 4332 |
|
|
2017
Q1 | $479K | Buy |
+9,800
| New | +$447K | ﹤0.01% | 4072 |
|
|
2016
Q4 | – | Sell |
-219,000
| Closed | -$8.27M | – | 8204 |
|
|
2016
Q3 | $8.27M | Buy |
219,000
+29,000
| +15% | +$1.09M | ﹤0.01% | 1576 |
|
|
2016
Q2 | $6.39M | Buy |
+190,000
| New | +$6.7M | ﹤0.01% | 1745 |
|
|
2015
Q3 | – | Sell |
-200
| Closed | -$6K | – | 8791 |
|
|
2015
Q2 | $6K | Hold |
200
| – | – | ﹤0.01% | 7812 |
|
|
2015
Q1 | $6K | Buy |
+200
| New | +$5.62K | ﹤0.01% | 8037 |
|
Other funds holding MDCO
UBS Group's MDCO Position: Q1 2020 in Review
UBS Group sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 1,277,342 shares — an estimated $108M sold.
UBS Group first reported a position in MDCO in Q4 2014 and held it in 21 quarters. The position peaked at $108M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- UBS Group reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 1,277,342 Medicines Co shares in Q1 2020, an estimated $108M.
- UBS Group first reported a position in Medicines Co in Q4 2014 and held it in 21 quarters.
- UBS Group's Medicines Co position peaked at $108M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.